AR and posterior cortical atrophy: However, the targeting androgen/AR agents have been employed to treat PCa patients with a short-term survival benefit while the severe adverse effects of these agents lead to CRPC and/or the metastatic status as a result in lethal aggressiveness [38,39,40].